Persistent neuropsychiatric symptoms after COVID-19: a systematic review and meta-analysis
The nature and extent of persistent neuropsychiatric symptoms after COVID-19 are not established. To help inform mental health service planning in the pandemic recovery phase, we systematically determined the prevalence of neuropsychiatric symptoms in survivors of COVID-19. <br> For this pre-r...
| Asıl Yazarlar: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Diğer Yazarlar: | |
| Materyal Türü: | Journal article |
| Dil: | English |
| Baskı/Yayın Bilgisi: |
Oxford University Press
2021
|
| _version_ | 1826292236386566144 |
|---|---|
| author | Badenoch, J Rengesamy, E Watson, C Jansen, K Chakraborty, S Sundaram, R Hafeez, D Burchill, E Saini, A Thomas, L Cross, B Hunt, C Conti, I Ralovska, S Hussain, Z Butler, M Pollak, T Koychev, I Michael, B Holling, H Rogers, J Rooney, A |
| author2 | SARS-CoV-Neuro Collaboration |
| author_facet | SARS-CoV-Neuro Collaboration Badenoch, J Rengesamy, E Watson, C Jansen, K Chakraborty, S Sundaram, R Hafeez, D Burchill, E Saini, A Thomas, L Cross, B Hunt, C Conti, I Ralovska, S Hussain, Z Butler, M Pollak, T Koychev, I Michael, B Holling, H Rogers, J Rooney, A |
| author_sort | Badenoch, J |
| collection | OXFORD |
| description | The nature and extent of persistent neuropsychiatric symptoms after COVID-19 are not established. To help inform mental health service planning in the pandemic recovery phase, we systematically determined the prevalence of neuropsychiatric symptoms in survivors of COVID-19.
<br>
For this pre-registered systematic review and meta-analysis (PROSPERO ID CRD42021239750) we searched MEDLINE, EMBASE, CINAHL and PsycINFO to 20th February 2021, plus our own curated database. We included peer-reviewed studies reporting neuropsychiatric symptoms at post-acute or later time-points after COVID-19 infection, and in control groups where available. For each study a minimum of two authors extracted summary data. For each symptom we calculated a primary pooled prevalence using generalised linear mixed models. Heterogeneity was measured with I
2. Subgroup analyses were conducted for COVID-19 hospitalisation, severity, and duration of follow-up.
<br>
From 2,844 unique titles we included 51 studies (n=18,917 patients). The mean duration of follow-up after COVID-19 was 77 days (range 14-182 days). Study quality was most commonly moderate. The most
prevalent neuropsychiatric symptom was sleep disturbance (pooled prevalence=27·4% [95%CI 21·4-34·4%]), followed by fatigue (24·4% [17·5-32·9%]), objective cognitive impairment (20·2% [10·3-35·7%]), anxiety (19·1%[13·3-26·8%]), and post-traumatic stress (15·7% [9·9-24·1%]). Only two studies reported symptoms in control groups, both reporting higher frequencies in COVID-19 survivors versus controls. Between-study heterogeneity was high (I 2=79·6%-98·6%). There was little or no evidence of differential symptom prevalence based on hospitalisation status, severity, or follow-up duration.
<br>
Neuropsychiatric symptoms are common and persistent after recovery from COVID-19. The literature on longer-term consequences is still maturing, but indicates a particularly high prevalence of insomnia, fatigue, cognitive impairment, and anxiety disorders in the first six months after infection. |
| first_indexed | 2024-03-07T03:11:34Z |
| format | Journal article |
| id | oxford-uuid:b45f838e-3a0c-4c22-88a0-ab95493abc31 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:11:34Z |
| publishDate | 2021 |
| publisher | Oxford University Press |
| record_format | dspace |
| spelling | oxford-uuid:b45f838e-3a0c-4c22-88a0-ab95493abc312022-03-27T04:25:47ZPersistent neuropsychiatric symptoms after COVID-19: a systematic review and meta-analysisJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:b45f838e-3a0c-4c22-88a0-ab95493abc31EnglishSymplectic ElementsOxford University Press2021Badenoch, JRengesamy, EWatson, CJansen, KChakraborty, SSundaram, RHafeez, DBurchill, ESaini, AThomas, LCross, BHunt, CConti, IRalovska, SHussain, ZButler, MPollak, TKoychev, IMichael, BHolling, HRogers, JRooney, ASARS-CoV-Neuro CollaborationThe nature and extent of persistent neuropsychiatric symptoms after COVID-19 are not established. To help inform mental health service planning in the pandemic recovery phase, we systematically determined the prevalence of neuropsychiatric symptoms in survivors of COVID-19. <br> For this pre-registered systematic review and meta-analysis (PROSPERO ID CRD42021239750) we searched MEDLINE, EMBASE, CINAHL and PsycINFO to 20th February 2021, plus our own curated database. We included peer-reviewed studies reporting neuropsychiatric symptoms at post-acute or later time-points after COVID-19 infection, and in control groups where available. For each study a minimum of two authors extracted summary data. For each symptom we calculated a primary pooled prevalence using generalised linear mixed models. Heterogeneity was measured with I 2. Subgroup analyses were conducted for COVID-19 hospitalisation, severity, and duration of follow-up. <br> From 2,844 unique titles we included 51 studies (n=18,917 patients). The mean duration of follow-up after COVID-19 was 77 days (range 14-182 days). Study quality was most commonly moderate. The most prevalent neuropsychiatric symptom was sleep disturbance (pooled prevalence=27·4% [95%CI 21·4-34·4%]), followed by fatigue (24·4% [17·5-32·9%]), objective cognitive impairment (20·2% [10·3-35·7%]), anxiety (19·1%[13·3-26·8%]), and post-traumatic stress (15·7% [9·9-24·1%]). Only two studies reported symptoms in control groups, both reporting higher frequencies in COVID-19 survivors versus controls. Between-study heterogeneity was high (I 2=79·6%-98·6%). There was little or no evidence of differential symptom prevalence based on hospitalisation status, severity, or follow-up duration. <br> Neuropsychiatric symptoms are common and persistent after recovery from COVID-19. The literature on longer-term consequences is still maturing, but indicates a particularly high prevalence of insomnia, fatigue, cognitive impairment, and anxiety disorders in the first six months after infection. |
| spellingShingle | Badenoch, J Rengesamy, E Watson, C Jansen, K Chakraborty, S Sundaram, R Hafeez, D Burchill, E Saini, A Thomas, L Cross, B Hunt, C Conti, I Ralovska, S Hussain, Z Butler, M Pollak, T Koychev, I Michael, B Holling, H Rogers, J Rooney, A Persistent neuropsychiatric symptoms after COVID-19: a systematic review and meta-analysis |
| title | Persistent neuropsychiatric symptoms after COVID-19: a systematic review and meta-analysis |
| title_full | Persistent neuropsychiatric symptoms after COVID-19: a systematic review and meta-analysis |
| title_fullStr | Persistent neuropsychiatric symptoms after COVID-19: a systematic review and meta-analysis |
| title_full_unstemmed | Persistent neuropsychiatric symptoms after COVID-19: a systematic review and meta-analysis |
| title_short | Persistent neuropsychiatric symptoms after COVID-19: a systematic review and meta-analysis |
| title_sort | persistent neuropsychiatric symptoms after covid 19 a systematic review and meta analysis |
| work_keys_str_mv | AT badenochj persistentneuropsychiatricsymptomsaftercovid19asystematicreviewandmetaanalysis AT rengesamye persistentneuropsychiatricsymptomsaftercovid19asystematicreviewandmetaanalysis AT watsonc persistentneuropsychiatricsymptomsaftercovid19asystematicreviewandmetaanalysis AT jansenk persistentneuropsychiatricsymptomsaftercovid19asystematicreviewandmetaanalysis AT chakrabortys persistentneuropsychiatricsymptomsaftercovid19asystematicreviewandmetaanalysis AT sundaramr persistentneuropsychiatricsymptomsaftercovid19asystematicreviewandmetaanalysis AT hafeezd persistentneuropsychiatricsymptomsaftercovid19asystematicreviewandmetaanalysis AT burchille persistentneuropsychiatricsymptomsaftercovid19asystematicreviewandmetaanalysis AT sainia persistentneuropsychiatricsymptomsaftercovid19asystematicreviewandmetaanalysis AT thomasl persistentneuropsychiatricsymptomsaftercovid19asystematicreviewandmetaanalysis AT crossb persistentneuropsychiatricsymptomsaftercovid19asystematicreviewandmetaanalysis AT huntc persistentneuropsychiatricsymptomsaftercovid19asystematicreviewandmetaanalysis AT contii persistentneuropsychiatricsymptomsaftercovid19asystematicreviewandmetaanalysis AT ralovskas persistentneuropsychiatricsymptomsaftercovid19asystematicreviewandmetaanalysis AT hussainz persistentneuropsychiatricsymptomsaftercovid19asystematicreviewandmetaanalysis AT butlerm persistentneuropsychiatricsymptomsaftercovid19asystematicreviewandmetaanalysis AT pollakt persistentneuropsychiatricsymptomsaftercovid19asystematicreviewandmetaanalysis AT koychevi persistentneuropsychiatricsymptomsaftercovid19asystematicreviewandmetaanalysis AT michaelb persistentneuropsychiatricsymptomsaftercovid19asystematicreviewandmetaanalysis AT hollingh persistentneuropsychiatricsymptomsaftercovid19asystematicreviewandmetaanalysis AT rogersj persistentneuropsychiatricsymptomsaftercovid19asystematicreviewandmetaanalysis AT rooneya persistentneuropsychiatricsymptomsaftercovid19asystematicreviewandmetaanalysis |